The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- These N.J. medical schools are among some of the best in the country. See how they rank.
- Estrogen Patch Shortages Are Ongoing—Here’s Where to Find Them and What to Ask Your Doctor.
- Toddlers are getting their hands on e-cigarettes and inhaling at an alarming rate, new Rutgers study shows.
- Rutgers deans: We train advanced practice nurses for N.J. Our laws send them elsewhere.
- Push for raw milk intensifies across the US, despite illness outbreaks and scientists’ warnings.
Categories
- Community (2,495)
- Covid (1,001)
- CTO Events (6)
- News (3,167)
- Pilots (21)